Merck Research Development from 2010 to 2026

MRK Stock  USD 110.27  1.93  1.78%   
Merck Research Development yearly trend continues to be quite stable with very little volatility. Research Development may rise above about 21.7 B this year. From the period between 2010 and 2026, Merck, Research Development regression line of its data series had standard deviation of  6,987,268,448 and standard deviation of  6,987,268,448. View All Fundamentals
 
Research Development  
First Reported
1994-03-31
Previous Quarter
B
Current Value
4.2 B
Quarterly Volatility
1.8 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.5 B or Total Revenue of 77.5 B, as well as many indicators such as Price To Sales Ratio of 4.53, Dividend Yield of 0.0238 or PTB Ratio of 6.9. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.
  
Build AI portfolio with Merck Stock
Check out the analysis of Merck Correlation against competitors.
Historical Research Development data for Merck serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Merck Company represents a compelling investment opportunity.

Latest Merck's Research Development Growth Pattern

Below is the plot of the Research Development of Merck Company over the last few years. It is Merck's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Merck Research Development Regression Statistics

Arithmetic Mean12,306,978,529
Geometric Mean10,281,359,285
Coefficient Of Variation56.77
Mean Deviation5,160,113,391
Median10,261,000,000
Standard Deviation6,987,268,448
Sample Variance48821920.4T
Range29.4B
R-Value0.83
Mean Square Error15898558.3T
R-Squared0.69
Significance0.000032
Slope1,153,290,637
Total Sum of Squares781150725.9T

Merck Research Development History

202621.7 B
202520.6 B
202417.9 B
202330.5 B
202213.5 B
202112.2 B
202013.4 B

About Merck Financial Statements

Merck investors utilize fundamental indicators, such as Research Development, to predict how Merck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development20.6 B21.7 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. Expected growth trajectory for Merck significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Merck assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.87
Dividend Share
3.2
Earnings Share
7.56
Revenue Per Share
25.559
Quarterly Revenue Growth
0.037
Understanding Merck Company requires distinguishing between market price and book value, where the latter reflects Merck's accounting equity. The concept of intrinsic value—what Merck's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Merck's price substantially above or below its fundamental value.
Understanding that Merck's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Merck represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Merck's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.